Kodak stock surges 98% after federal watchdog finds no problems with halted $765 million government loan
Kodak shares soared as much as 98% in pre-market trading on Monday after a government watchdog found no problems with the process that created a $765 million federal loan to finance the camera company's pivot toward making COVID-19 drug ingredients earlier this year.
The inspector general of the US International Development Finance Corporation, the agency behind the loan, delivered the results of his investigation to Sen. Elizabeth Warren in late November, The Wall Street Journal reported on Sunday. His assessment found no evidence of conflicts of interest or misconduct among the agency's employees.
Read More: Goldman Sachs says buy these 19 beaten-down stocks on its 'holiday shopping list' that are poised to break out in the 1st quarter of 2021
The DFC signed a letter of interest on July 28 to provide the $765 million loan to Kodak under the Defense Production Act, which requires companies to accept and prioritize government contracts for national security and other reasons.
Kodak said it would use the funding to launch a pharmaceutical division that would make generic-drug ingredients in critically short supply. Trump described the agreement as "one of the most important deals in the history of US pharmaceutical industries."
Read More: Billionaire investor Ray Dalio breaks down how US debt and money-printing binges have formed a 'classic toxic mix' that could set it on a downward spiral towards revolution and civil war
News of the deal sent Kodak's stock price up as much as 2,190% in two days, briefly boosting its market capitalization to north of $4.6 billion.
However, it plummeted within days after the Securities and Exchange Commission launched an investigation and Democratic politicians including Warren expressed concerns about the loan.
Comments
Post a Comment